Middle East & Africa Therapeutic Vaccines Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis
No. of Pages: 122 | Report Code: BMIRE00032093 | Category: Life Sciences
No. of Pages: 122 | Report Code: BMIRE00032093 | Category: Life Sciences
The Middle East & Africa therapeutic vaccines market size is expected to reach US$ 4,471.70 thousand by 2031 from US$ 2,358.36 thousand in 2024. The market is estimated to record a CAGR of 9.6% from 2024–2031.
The Middle East and Africa (MEA) therapeutic vaccines market is experiencing steady growth, driven by increasing awareness of chronic and infectious diseases such as cancer, HIV, and hepatitis. Governments across the region are investing more in healthcare infrastructure, and international partnerships are contributing to research and development. However, limited access to advanced medical technologies and high vaccine development costs remain key challenges. Countries like South Africa, Saudi Arabia, and the UAE are emerging as focal points due to their growing biotech sectors and supportive health policies. Additionally, the rising prevalence of non-communicable diseases and a shift toward personalized medicine are creating demand for targeted immunotherapies. Although still in its early stages compared to Western markets, the MEA region presents significant long-term opportunities for stakeholders involved in therapeutic vaccine development and distribution, especially as regulatory frameworks and healthcare access continue to improve.
Middle East & Africa Therapeutic Vaccines Market Strategic Insights
Get more information on this report Middle East & Africa Therapeutic Vaccines Market Segmentation Analysis
Key segments that contributed to the derivation of the therapeutic vaccines market analysis are product, technology, and end user.
Developing vaccines against emerging pathogens that possess the potential to cause pandemics is not feasible using conventional technologies. As a result, it is important to develop platforms that can respond rapidly to pandemic threats and adapt effectively to measures taken to tackle emerging variants. Innovative vaccine platforms—such as mRNA vaccines, immuno-material-based vaccine technology, nano-drug delivery systems, and viral vector-based vaccines—are revolutionizing the development of therapeutic vaccines. Further, the shift toward more efficient and customizable vaccine technologies has enabled the development of vaccines that can target several diseases, including cancers, autoimmune conditions, and infectious diseases. The success of mRNA COVID-19 vaccine technology showcases promises in the potential of mRNA technology for therapeutic applications beyond infectious diseases, including cancer and chronic infections. These platforms allow for quicker, more flexible, and better scalable vaccine production, accelerating the development of new therapeutic vaccines.
Researchers are developing novel platforms for future applications. For instance, a research team at the Wyss Institute at Harvard University is developing a pioneering vaccine platform known as OMNIVAX. This "first-in-class immuno-material-based" vaccine technology aims to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial infections. Upon injection, OMNIVAX vaccines establish a scaffold to attract dendritic immune cells, programming them to target a specific antigen. The cells are then released, followed by their migration to nearby lymph nodes, where they initiate a systemic and prolonged immune response. Using modular technology, multiple antigens can be incorporated into a single OMNIVAX vaccine.
Different nano-drug delivery systems are currently being developed to enhance the precision of cancer vaccines and improve the uptake of neoantigens by dendritic cells. These systems include lipid nanoparticles, bacteria-derived outer membrane vesicles, exosomes, and amphiphilic vaccines. Personalized dendritic cell-mimicking nanovaccine, i.e., nanoDC vaccine, which utilizes components from Escherichia coli and tumor cells, has emerged as a promising approach. It effectively delivers tumor-associated antigens (TAAs) and promotes maturation in bone marrow-derived cells by stimulating the interferon genes signaling pathway. Overall, the development of these nano-drug delivery systems holds great promise for improving the efficacy of cancer vaccines by enhancing the delivery efficiency of neoantigens to dendritic cells in lymph nodes.
Such modern approaches have the potential to enhance the generation of antigen-specific T-cell response, ultimately improving clinical outcomes for patients with solid tumors. Thus, next-generation platforms, such as mRNA and DNA-derived vaccines, offer a promising path for vaccine development due to their low costs, safety, high potency, and rapid mass deployment capabilities. These platforms are relevant for safeguarding humans against complex pathogens with immune evasion potential. Moreover, unlike conventionally derived vaccines, these innovative platforms are likely to offer effective solutions for non-infectious diseases. The use of advanced delivery systems to enhance the effectiveness and immune response of vaccines would further improve the prospects of therapeutic vaccines. These innovative vaccine platforms are emerging as significant trends in the therapeutic vaccines market owing to their ability to contribute to greater success rates in clinical trials and improvements in efficacy, safety, and patient outcomes.
Based on Geography, the Middle East & Africa therapeutic vaccines market comprises the Saudi Arabia, South Africa, the UAE and the Rest of Middle East & Africa. Saudi Arabia held the largest share in 2024.
Saudi Arabia presents significant growth opportunities for the therapeutic vaccines market, driven by key growth-enabling factors such as increasing healthcare needs with the rising prevalence of chronic diseases and cancer, and government support for biotechnology. As per GLOBOCAN 2020 data, the country recorded ~27,885 new cancer cases, and the number is expected to rise to 60,429 by 2040. The country's healthcare system recognizes the need for innovative treatments, including therapeutic vaccines, and there is growing interest in vaccines that can target specific cancer indication.
Saudi Arabia holds immense potential for the therapeutic vaccines market with a growing population and an expanding healthcare infrastructure. As per the "Rights and Wellbeing of Older Persons in Saudi Arabia" report, the number of people aged 60 or more is projected to increase five-fold during 2020–2050, rising from 2 million (5.9% of the total population) to 10.5 million (23.7% of the population). Also, the number of people aged 80 or more is expected to reach 1.6 million, i.e., 4% of the total population by 2050. As the demographic landscape shifts, with an increasing number of individuals aged 60 and above, the country is likely to generate a notable demand for healthcare solutions tailored to the unique needs of older adults, as this population is more susceptible to chronic diseases and infections. Thus, Saudi government's commitment to enhancing healthcare services for the elderly, coupled with increased healthcare expenditure, creates a favorable environment for the introduction and adoption of innovative vaccine therapies.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 2,358.36 Thousand |
| Market Size by 2031 | US$ 4,471.70 Thousand |
| CAGR (2024 - 2031) | 9.6% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | Middle East and Africa
|
| Market leaders and key company profiles |
|
Some of the key players operating in the market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
The following methodology has been followed for the collection and analysis of data presented in this report:
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis, and gain valuable insights. These research interviews are designed to:
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
The Middle East & Africa Therapeutic Vaccines Market is valued at US$ 2,358.36 Thousand in 2024, it is projected to reach US$ 4,471.70 Thousand by 2031.
As per our report Middle East & Africa Therapeutic Vaccines Market, the market size is valued at US$ 2,358.36 Thousand in 2024, projecting it to reach US$ 4,471.70 Thousand by 2031. This translates to a CAGR of approximately 9.6% during the forecast period.
The Middle East & Africa Therapeutic Vaccines Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Therapeutic Vaccines Market report:
The Middle East & Africa Therapeutic Vaccines Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa Therapeutic Vaccines Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa Therapeutic Vaccines Market value chain can benefit from the information contained in a comprehensive market report.
E 1803, Panchshil Towers, Vagholi, Haveli, Pune- 412207, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East & Africa Therapeutic Vaccines Market
